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Abstract 
Objective: To determine the association between incident proton pump inhibitor (PPI) use 
and Clostridium difficile infections across multiple countries 
Method:  National data covering the total population in Australia and Korea, the Canadian 
population over 65 years and a 3 million person random sample data set from Taiwan were 
assessed, as were data from a worker insurance population and a hospital inpatient/ outpatient 
population in Japan. Sequence symmetry analysis was used to assess the association with oral 
vancomycin dispensing as the outcome of interest. 
Results: 54,957 patients were included. Positive associations were observed in Australia; 
adjusted sequence ratio (ASR) 2.48 (95% CI 1.90, 3.12), Korea ASR 2.15 (95%CI 2.11, 
2.19), Canada ASR 1.45 (95% CI 1.16, 1.79), Japan hospital dataset ASR 3.21 (95%CI 2.12, 
4.55) and Japan worker insurance dataset ASR 5.40 (95% CI 2.73, 8.75).  The pooled result 
was ASR 2.40 (95%CI 1.88, 3.05) and 3.16 (95%CI 1.95, 5.10) when limited to Japan, 
Korean and Taiwan. Results did not vary by individual PPI. The temporal analysis showed 
effects within the first two weeks of PPI initiation. 
Conclusion: Our study confirms the association between PPI initiation and C. difficile 
infections across countries in the Asia-Pacific region.   
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1. Introduction 
There is a significant body of research showing an association between use of proton pump 
inhibitors and Clostridium difficile infections,[1, 2, 3, 4, 5] however, limited research has 
been undertaken in Asia-Pacific populations.  A 2012 meta-analysis assessing the association 
between C. difficile infections and proton pump inhibitor use included 51 studies and reported 
a pooled odds ratio of 1.65 (95% CI 1.47, 1.85), however, only 3 observations were from the 
Asia region.[1]  When analysis was limited to the Asian observations, and the pooled result 
was higher at OR 3.26, (95%CI 1.91 -5.58.).[1] 
The prevalence of different strains of C. difficile varies substantially by region. Ribotyping 
has shown that the most frequent ribotypes in Australia are 014 and 002,[6] in China it is 017, 
046, and 012; in  Japan 018, 014, 002, 001,  Korea 018, 017, Taiwan 017, and Hong Kong it 
is 002.[7]  This compares with Europe where the ribotypes are 027, 014,001/072, and 078.[8]  
This may have implications for the risk of C. difficile infections from proton pump inhibitors. 
In some C. difficile ribotypes the level of expression of toxin genes and their regulators was 
greater at higher pH levels and elevated even further in the presence of PPIs.[9] For ribotype 
001, PPI exposure was associated with a 120-fold higher expression of tcdA at higher pH 
levels, while for ribotypes 027 and 028, more than 50 fold increases were observed at higher 
pH levels.  For tcdB and cdtB expression the relationship was less clear.[9]    Whether the 
differing prevalence of different strains of C. difficile and the potential for PPIs to affect toxin 
gene expression differently according to strain means that differences in risk of PPI induced 
C. difficile can be observed across countries is unclear.  
There have been only limited studies of the association between proton pump inhibitors and 
risk of C. difficile infection in the Asia Pacific region, with the majority of studies undertaken 
to date being from North America or Europe (48 of 51).[1] No multi-country studies have 
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been undertaken to date. Further many studies have been single centre sites (40 of 51), have 
been undertaken in the hospital setting (37 of 51, 6 involved both hospital and community 
and 8 involved community only) and have been case-control studies (37 of 51).[1]  The 
majority of studies assessed any proton pump inhibitor exposure with limited analysis of the 
effect of incident use.  
This research aimed to establish the risk of C. difficile infections associated with initiation of 
PPIs in countries in the Asia-Pacific region. We undertook a multi-country study, which 
included 4 countries (6 databases) from the Asia Pacific region.  We also included data from 
Canada which provided a contemporary reference point, as much of the previous research had 
been undertaken in North America or Europe.[1]  We used sequence symmetry analysis,[10] 
which has the advantage of inherently controlling for measured and unmeasured confounders 
that are stable over time.  All prior research has used cohort or case-control study designs 
which may have residual confounding due to unmeasured confounders.  We had national data 
for four of the countries involved, thus providing the largest study sample to date to assess 
the association between proton pump inhibitor use and C. difficile infection. 
2. Methods 
 
2.1 Data sources 
This multi country study was initiated by Health Canada, with participation from the member 
groups of the Asian PharmacoEpidemiology Network (AsPEN).[11] AsPEN provides a 
mechanism to support the conduct of cross-country pharmacoepidemiological research to 
facilitate prompt detection and communication of emerging safety issues between countries. 
The data sources used are listed in table 1, with full details of the databases published 
elsewhere.[12] All datasets held patient level dispensing data which included: a patient 
identifier, patient demographics, date of medicine supply, medicine dispensed, quantity and 
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strength. Medicines were mapped from individual country specific codes to the WHO 
Anatomical Therapeutic Chemical (ATC) classification codes.[13]  
2.2 Study design 
We used sequence symmetry analysis,[10] that compares the sequence by which people 
initiate the same two medicines within a defined period of time.[10]  The method has been 
validated as an adverse event signal detection tool against adverse events identified in 
randomised controlled trials and against negative controls from product information of 
unrelated products, as well as in a simulation study.[14] [15] It’s performance has been 
shown to be similar to disproportionality methods.[14]    
We assessed the association between proton pump inhibitor use and C. difficile using oral 
vancomycin as the marker medicine for C. difficile. Oral vancomycin use would be expected 
to rise after PPI initiation if there was an association with C. difficile infection as oral 
vancomycin is only indicated for C. difficile infections and staphylococcal enterocolitis.[16] 
Oral vancomycin has been used as a marker of C. difficile infections in previous research.[17] 
Vancomycin’s poor absorption from the gastrointestinal tract makes it unsuitable for other 
types of infection, so risk of misclassification bias was low.    
A distributive network model [18] was employed. The co-ordinating centre for this study, the 
University of South Australia, developed the statistical analysis code as a stand-alone SAS 
program for execution by each participant in their home institution. The SAS program used 
global macro variables. Participants executed the SAS code and a standardised file of 
summary results was returned to the co-ordinating centre for collation. These standardised 
files included graphics of the number of people dispensed the study medicines each month 
(prevalent population), the number of people starting study medicines each month (incident 
8 
 
population), and the results of the sequence symmetry analyses (SSA) results including the 
graphics showing temporal sequences.  
The primary outcome was the first dispensing of oral vancomycin (ATC code C03CA01) as 
an indicator medicine for C.difficile infection.  Oral vancomycin was only used in Taiwan at 
the beginning of the study period, with injectable formulations of vancomycin used orally at 
both the beginning of the study and in subsequent years.  Hong Kong used injectable forms of 
vancomycin orally throughout the study period, thus, Hong Kong data were not included in 
the results.  Proton pump inhibitors assessed included omeprazole, esomeprazole, 
lansoprazole, pantoprazole and rabeprazole.  Proton pump inhibitors dispensed as part of a 
helicobacter eradication therapy co-pack were excluded.  We included a sensitivity analysis, 
where metronidazole was used as the indicator medicine.  Metronidazole is used first line in 
many settings for treatment of C.difficile infections, however, it is also used for conditions 
other than C.difficile infection, so is not as specific an indicator. 
In the SSA method, the date of incident dispensing of proton pump inhibitors and oral 
vancomycin was determined for each individual patient. All incident dispensings that 
occurred within one year of each other for the same person were included in the analysis. We 
excluded patients who initiated any of the study medicines in the first year of data coverage 
in any dataset to ensure we limited the analyses to incident users. The SSA method[10]  is 
sensitive to prescribing trends over time and adjustment was made for temporal trends using 
the null-effect sequence ratio as described by Tsiropolous.[19] Bootstrapped 95% confidence 
intervals (CI) were obtained using 500 replicates.  The SSA analyses were restricted to 
sequences of incident dispensings within 12 months of each other to limit the effect of age 
and other potential time-varying covariates on the probability of exposure and outcome. 
Moreover, a 12-month period has better specificity and positive predictive value compared 
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with shorter periods.[14] Pooled estimates were obtained with a random effects model, using 
the generic inverse variance method.[20] 
3. Results 
In total, 54,957 patients who received oral vancomycin and proton pump inhibitors were 
included in the study. Positive associations were see in all countries apart from Taiwan, 
where due to low use of oral vancomycin, insufficient numbers were available to determine 
effect (Table 2). The pooled estimate showed a 2.4 fold (95% CI 1.88-3.05) increased risk 
(figure 1).  When limited to the Asian countries (Japan, Korea and Taiwan) the pooled 
estimate was 3.16 (95%CI 1.95, 5.10). The temporal relationship was apparent in all 
countries, with effects being observed within the first two weeks of treatment (See figure 2 
shows results for Australia (national) and Japan Medical Data Centre (JMDC), data for other 
countries not shown).  Results for the individual PPIs are presented in table 3 for Australia 
(national) and Korea, the only countries with sufficient numbers to undertake individual 
agent analysis, and show similar risk for each agent.  Our sensitivity analysis with 
metronidazole as the outcome indicator showed similar results (Figure 3).  
4. Discussion 
This multi-country study found an elevated risk of C. difficile infections after initiation of 
proton pump inhibitors. Our pooled estimate of 2.4 (95% CI 1.88-3.05) is slightly higher but 
consistent with prior research, where meta-analysis evidence reported an increased odds of 
1.65 (95% CI 1.47-1.85). [1]  When our pooled analysis was limited to Korea, Japan and 
Taiwan, we found a three-fold increased risk which is also consistent with previous meta-
analysis results from Asian countries OR 3.26, (95%CI 1.91 -5.58.).[1]  The risk was present 
and was of similar magnitude for each individual proton pump inhibitor. 
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We observed the highest risk in the Japanese data sets, with risk estimates increased three and 
five fold respectively in the two Japanese data sets, for which confidence intervals 
overlapped.  These results are higher risk estimates than have been reported previously in 
Japan.  The largest previous Japanese study, which was a multi-institution study involving 
1025 cases and 878 controls that assessed hospital acquired C. difficile infections, did not find 
proton pump inhibitors were a risk factor for C. difficile infections, however, assessment of 
PPI use was limited to that prescribed during the hospital stay.[21] By comparison our results 
include outpatient proton pump inhibitor use up to one year prior to C. difficile infections. A 
small Japanese study, limited to 26 cases and 52 controls, assessed risk factors for community 
acquired C. difficile infections, finding no association with proton pump inhibitor use.[22]  
Another small study of risk of recurrent infection, involving 14 patients with recurrent 
infection and 62 without also did not find a significant effect of proton pump inhibitors on 
recurrence.[23]  These latter two studies may have had insufficient sample size to 
demonstrate effect. Finally, a Japanese study amongst a cohort of people who had been 
prescribed injectable antibiotics did find proton pump inhibitors were associated with 
increased risk of subsequent C. difficile infections.[24]   Previous research in Korea has 
assessed the relationship between recurrent C. difficile infections and PPIs, demonstrating an 
association.[25, 26] No prior studies from Korea examined the effect on incident infection.  
One small study involving 84 persons from Taiwan found proton pump inhibitors were an 
independent risk factor for development of C. difficile infections (OR 3.2, p=0.014)[27], 
while a second study found of those with C. difficile colonization, use of proton pump 
inhibitors was more common in those who subsequently developed infection.[28]   
While it has been postulated that the acid suppressions mechanism of PPIs may play a role by 
allowing C. difficile spores to survive the gastric environment, this may not be the mechanism 
as C. difficile spores can survive acid gastric contents.[29]  Acid levels, though, may affect 
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toxin expression. As we previously noted, one in-vitro study found that expression of toxin 
genes and their regulators were different in the presence of PPIs in some C. difficile 
ribotypes.[9] Another in vitro study also examining the effect of PPIs on expression of 
colonocyte genes found PPIs decreased their expression.[30] The consequence of decreased 
expression includes loss of maintenance of cell junction, and reduced production of proteins 
known to protect the intestinal epithelium, one of which is known to protect against C. 
difficile induced intestinal damage. An effect on bile acid metabolism and transport was also 
observed.[30]  All of these effects have the potential to increase susceptibility to or worsen C. 
difficile infection. 
Given one of the possible mechanisms by which PPIs may exert their influence on C. difficile 
infection is toxin expression and that toxin expression differs by ribotype,[9] our results, 
highlight the importance of obtaining risk estimates, where possible, from local data as data 
from other countries may not be directly applicable. Our results show slightly higher risk 
estimates in the Asian countries, however, we did not have access to clinical records and so 
could not ascertain any information on whether this could be related to the strain of C. 
difficile being treated.  Another possible reason for higher risk estimates in the Asian 
countries, and Japan in particular, is because of inter-ethnic differences in the prevalence of 
CYP2C19 polymorphisms.  There is a higher prevalence of the poor metaboliser phenotype 
of CYP2C19 in the Japanese (18-22.5%) and the Koreans (12.6%) compared to Caucasian 
populations (2.5-3.5%).  The poor metaboliser phenotype results in raised and sustained 
plasma levels of PPIs, thus potentially increasing infection risk.[31] 
Strengths of our research include the access to national data sets for Australia, Canada, 
Korea, and Taiwan. Our research used a common method and a common analytic approach 
which ensures results are comparative with regards to method and data variables used. This is 
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the first study of this association using a within person design, which has the advantage of 
inherently adjusting for measured and unmeasured confounders that are stable over time.[10] 
A prior study utilising SSA demonstrated that patient characteristics are often similar in the 
causal and non-causal groups and therefore are unlikely to affect the sequence order 
providing further support that the method effectively adjusts for stable confounders.[10]  
Given the association between C. difficile infections and PPIs has been previously 
described,[1, 2, 3, 4, 5] there is potential for prescribers who are aware of the association to 
minimise prescribing PPIs in people with C. difficile infections.  However, our temporal 
analysis shows an increase in oral vancomycin initiation in the non-causal groups, in the 
weeks immediately preceding PPI initiation, suggesting this potential confounding effect was 
not present to any great extent in our study (Figure 2). In addition the sequence symmetry 
method only includes persons who got both medicines, thus, eliminating the bias that could 
occur if those with no PPI prescription after C. difficile treatment were included.  
Additionally, our sensitivity analysis, using metronidazole as the outcome indicator, provides 
further evidence supporting the result.  
Limitations of our study include lack of diagnostic information at the outpatient level in the 
majority of countries, and hence the reliance on oral vancomycin as the proxy indicator for C. 
difficile infections. Oral vancomycin, however, has been used as a marker of C. difficile 
infection in previous research[17] and is the sole reimbursed indication for oral vancomycin 
in Australia[32],  Canada and Korea[33]. In Japan it is indicated for 1) “infectious enteritis 
(including pseudomembranous colitis)” caused by vancomycin-sensitive MRSA colitis and 
Clostridium difficile, and 2) “sterilization of gastrointestinal tract at bone-marrow 
transplantation”. In the other countries it may be used for either C. difficile or staphylococcal 
enterocolitis. A limitation of the method was the inability to include data from Hong Kong 
and the inclusion of only limited data from Taiwan. In both countries the injectable 
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formulation of vancomycin is used orally as a treatment for C. difficile infections and these 
dispensings could not be distinguished from vancomycin given in the injectable form for 
other reasons.  It is possible that injectable vancomycin was also given orally in countries 
outside Taiwan and Hong Kong, however, we were unable to ascertain the extent of this 
practice.  The implications of this means we may have missed some C. difficile infections, 
however, if this bias does exist, it is likely to have been systematic and not influenced one 
group more than the other.  A further limitation is that oral vancomycin is second line therapy 
in many countries, with metronidazole being first line therapy for C. difficile infections; 
including in Australia, Japan and Canada.  We did not use metronidazole as our primary 
indicator of C. difficile infections because metronidazole is also indicated for other conditions 
and thus may have biased the results.  This limitation means that we did not include cases of 
C. difficile treated by metronidazole only in our primary analysis and so will not have 
captured all events. In addition, there are differences in the extent of capture of C. difficile 
infections across data sets.  The Korean data set, which is a whole of country data set that 
includes hospital in-patient data, had the greatest number of C. difficile events.  The only 
other data set to include hospital infections was the Japan Hamamatsu data set.  All other data 
sets represent community treated infections.  While the community treated infections may 
have been less serious infections, our analysis shows the risk estimates were similar across all 
data sets, suggesting an effect due to proton pump inhibitor use and not to differences in data 
capture or health systems.   The variation in the data sets available limited our ability to 
assess differences in risk between countries.  The risk of protopathic bias, where PPIs may be 
used in the prodromal phase of the disease, is unlikely as indigestion type symptoms are not 
usually associated with C. difficile infections.  Further the temporal analysis shows that while 
the counts of persons receiving oral vancomycin is highest in the first few weeks post-
initiation, the effect remains elevated over time compared to those receiving oral vancomycin 
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prior to PPI initiation.  Finally, we cannot exclude the possibility that some of the differences 
observed across countries may be due to differences in health care practice.  
5. Conclusion 
Our study confirms the association between PPI initiation and C. difficile infections across 
countries in the Asia-Pacific region. Further research to confirm reasons underpinning any 
risk difference in the Asian region is required.  C. difficile infections are of growing concern 
across the world, particularly as resistance to treatments increases.[8, 34]  Use of proton 
pump inhibitors is a modifiable risk factor for clostridium difficile infections and clinicians 
need to take this into consideration when treating at-risk patients.   
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Table 1: Data sources for the study 
Data source Data type Population 
covered 
Years of 
coverage 
Comments 
DUSC secretariat, 
Australian Government 
Department of Human 
Services 
National 
pharmacy 
claims data  
23 million 
persons 
2003-2013 Excludes 
inpatient use in 
public hospitals 
Australian Government 
Department of 
Veterans’ Affairs 
Pharmacy 
claims data for 
Australian 
veterans and 
their dependents 
300,000 2001-2012 Excludes 
inpatient use in 
public hospitals. 
Predominantly 
older population 
(median age 80 
years) 
Canadian Institute for 
Health Information 
(CIHI)’s National 
Prescription Drug 
Utilization Information 
System (NPDUIS) 
Database 
National 
Pharmacy 
Claims from 
public drug 
programs 
 
3.5 million 2001-2012 Data from 7 
Canadian 
provinces 
included in this 
study.  
Includes 
population aged 
65 years and 
over who are 
eligible for 
coverage by 
provincial public 
drug programs. 
Includes only 
drugs dispensed 
in a community-
based setting.   
Hong Kong Clinical 
Data Analysis and 
Reporting System 
National 
electronic 
healthcare 
record of public 
hospitals and 
their ambulatory 
clinics.  
7 million 2008-2012 Oral 
vancomycin not 
reimbursed. 
Injectable 
formulation 
given orally. 
Japan Medical Data 
Center database 
Private health 
insurance data 
set for workers 
1,000,000 2008-2013  
Japan Hamamatsu 
Medical University 
Database 
Hospital data set 200,000 1996-2014 Includes all 
inpatient and 
outpatient 
dispensing 
Korea Health Insurance 
Review and 
National Health 
Insurance data 
50 million 2009-2013 Includes 
inpatient use 
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Assessment Service 
database (HIRA DB) 
set 
Taiwan National 
Health Insurance 
Research Database  
National Health 
insurance data 
set  
23 million 2001-2012 3 million person 
random sample 
data set utilised. 
Oral 
vancomycin not 
used after 2005. 
Injectable 
formulation 
given orally 
across whole 
time frame.  
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Table 2:  Sequence symmetry results for association between incident proton pump 
inhibitor (class) supply and incident oral vancomycin supply. 
 
Study 
Population 
n 
Oral 
vancomyci
n dispensed 
after  PPI 
N 
(Causal) 
Oral 
vancomyci
n dispensed 
before PPI
N 
(Non-
causal) 
Crude 
Sequence 
Ratio 
(causal/no
n-causal) 
Null 
Effect 
Sequence 
ratio 
Adjusted* 
sequence ratio 
(Crude SR/Null 
Effect SR)  
(95% confidence 
intervals) 
Korea 53820 37113 16707 2.22 1.03 2.15 (2.11-2.19)
Australia 351 257 94 2.734 1.10 2.48 (1.90-3.12)
Australia 
DVA 
77 49 28 1.75 0.99 1.76 (0.97-2.71)
Japan 
Hamamatsu 
171 128 43 2.98 0.93 3.21 (2.12-4.55)
Japan 
Medical 
Data Center 
139 116 23 5.04 0.93 5.40 (2.73-8.75)
Canada 388 270 118 2.29 1.58 1.45 (1.16-1.79) 
Taiwan# 11 8 3 2.67 0.99 2.70 (-1.60-8.91)
# Low numbers for Taiwan as a result of preferential use of injectable vancomycin 
* Adjusted for changing temporal trends in medicine use. 
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Table 3: Sequence symmetry results for association between incident proton pump 
inhibitor (individual agent) supply and incident oral vancomycin supply. 
 
Study 
Population 
Number of 
people with 
oral 
vancomycin 
dispensed 
after  PPI  
Number  of 
people with 
oral 
vancomycin 
dispensed 
before PPI 
Adjusted sequence 
ratio (95%confidence 
intervals) 
Omeprazole 
Australia 113 82 31 2.41 (1.45, 3.58) 
Korea 14878 9512 5366 1.67 (1.61, 1.72) 
Pantoprazole 
Australia 299 209 90 2.08 (1.57, 2.65) 
Korea 32070 20219 11851 1.71 (1.67, 1.75) 
Lansoprazole 
Australia 18 16 2 7.66 (1.76, 33.31*) 
Korea 25917 15731 10186 1.53 (1.50,1.57) 
Rabeprazole 
Australia 104 70 34 1.84 (1.10, 2.69) 
Korea 23021 15474 7547 2.07 (2.02, 2.13) 
Esomeprazole 
Australia 284 192 92 1.90 (1.44, 2.41) 
Korea 20261 12000 8261 1.67 (1.62, 1.71) 
* Due to small sample size, CI calculated using approximate interval estimation.[35] 
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Figure 1: Pooled estimate for association between incident proton pump inhibitor 
supply and incident oral vancomycin supply. 
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Figure 2:  Temporal relationship of incident PPI supply and incident vancomycin use 
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Figure 3: Pooled estimate for association between incident proton pump inhibitor 
supply and incident metronidazole supply. 
 
 
 
